Quest Diagnostics Unveils Groundbreaking ctDNA Test for Cancer Detection at ASCO Symposium
- Quest Diagnostics will present findings on ctDNA MRD testing at the 2026 ASCO Gastrointestinal Cancers Symposium.
- The Haystack MRD® test detects residual cancer through trace tumor-derived DNA in the bloodstream.
- Over 96% of oncologists support MRD testing for earlier cancer recurrence detection and personalized treatment strategies.
Advancements in Cancer Detection: Quest Diagnostics' Focus on ctDNA Testing
Quest Diagnostics, a leader in diagnostic information services, prepares to present groundbreaking findings on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing at the upcoming 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco. Scheduled for January 8-10, the symposium will showcase the Haystack MRD® test, developed by Quest's subsidiary, Haystack Oncology. This test represents a significant advancement in cancer monitoring, specifically designed to detect residual cancer through trace amounts of tumor-derived DNA found in the bloodstream.
The presentations will highlight two pivotal studies that underline the efficacy of the Haystack MRD test. The first study focuses on the reproducibility and clinical concordance of a tumor-informed MRD assay in patients who have undergone resection for colorectal cancer. The second study investigates the role of ctDNA in monitoring patients receiving total neoadjuvant treatment for locally advanced rectal adenocarcinoma. These insights are critical as they not only validate the test's reliability but also demonstrate its potential to improve patient outcomes by enabling earlier detection of cancer recurrence.
Recent findings from a Harris Poll survey reveal that an overwhelming 96% of oncologists believe MRD testing can identify cancer recurrence earlier than traditional methods. This strong consensus among healthcare professionals highlights the growing recognition of ctDNA MRD testing as a transformative tool for cancer management. By allowing clinicians to tailor surveillance strategies proactively and adjust treatment plans based on early detection, the Haystack MRD test exemplifies a shift towards more personalized cancer care. With over two decades of development in collaboration with experts from Johns Hopkins School of Medicine, the test is validated for commercial use in a CLIA-certified laboratory and is also available for clinical trials in various international locations.
In addition to its significant implications for cancer detection, the Haystack MRD test is part of a broader trend towards the integration of molecular diagnostics in oncology. As healthcare systems increasingly prioritize precision medicine, the role of ctDNA testing in guiding treatment decisions and improving patient management becomes even more crucial. The upcoming ASCO symposium will not only serve as a platform for Quest Diagnostics to present its latest findings but also as a vital forum for discussing the future of cancer diagnostics and treatment strategies.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

